Autoimmune Disease Featured Articles

  1. Using A Diabetes Patient's Own Liver Cells As A Novel Source Of Insulin 6/11/2012

    Diabetes currently afflicts approximately 285 million people worldwide, about 6.4 percent of the global population. The World Health Organization projects that this number is set to rise to 366 million by the year 2030. By Sarah Ferber, Ph.D., Chief Science Officer and founder, Orgenesis

  2. Are Your Foreign Manufacturing Sites FDA-Ready? 2/24/2012

    FDA inspections of overseas plants manufacturing pharmaceuticals and medical devices sold in the U.S. market are on the rise. The inspection frequency for a foreign manufacturing plant was once in nine years, as compared to once in 30 months for plants based in the United States, according to a 2010 GAO Report. By James Prutow, Frances Palomar, and Vignesh Ramesh

  3. A Novel Approach To Shortening The Drug Approval Process 12/14/2011
    Two pharmaceutical industry stories recently caught my attention. The first involves Nabi Biopharmaceuticals (NASDAQ: NABI), which recently announced the company's smoking cessation vaccine NicVAX failed a second late-stage trial.
  4. Integrative Biology: At The Tipping Point 10/7/2011

    I recently met Gustavo Salem, VP and general manager of the Biological Systems Division at Agilent Technologies. Salem believes integrative biology is at a tipping point for producing major breakthroughs in the drug development. By Rob Wright, Chief Editor, Life Science Leader magazine

  5. Article: Trial Recruitment Without 'Trial And Error:' Validating Protocols And Identifying Investigators With Secondary Data Sources 7/25/2011
    For the past 10 years, pharmaceutical marketers have been using comprehensive, secondary databases and sophisticated analytics to reach the right physicians with the right educational messages. That same information and analytical approach can be used just as effectively to help clinical research organizations (CROs) select investigators and reach the right potential subjects for clinical studies. By Michel Denarie, IMS Health